ClinicalTrials.Veeva

Menu
A

Advantage Clinical Trials | Bronx, NY

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ozanimod
ABT-494
Linaclotide
Upadacitinib
Tenapanor
Vonoprazan

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 11 total trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

Active, not recruiting
Crohn Disease
Other: Placebo
Drug: Ozanimod

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.

Active, not recruiting
Crohn Disease
Drug: Ozanimod

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

Active, not recruiting
Crohn Disease
Drug: Ozanimod
Other: Placebo

LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation...

Active, not recruiting
Functional Constipation
Irritable Bowel Syndrome With Constipation
Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)

VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the...

Active, not recruiting
Lyme Borreliosis
Biological: VLA15
Biological: Placebo

This study is to understand if the study vaccine (called VLA15) is safe in healthy children.We are looking for children who:* are healthy* are age 5...

Active, not recruiting
Lyme Disease
Biological: VLA15
Other: Normal Saline

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediat...

Enrolling
Irritable Bowel Syndrome With Constipation (IBS-C)
Drug: Tenapanor 50 MG
Drug: Placebo

Trial sponsors

AbbVie logo
Celgene logo
Pfizer logo
Ardelyx logo
Phathom Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems